This product is a film-coated tablet, which is yellowish after removing the film coat.
It is indicated for the treatment of schizophrenia and psychosis in acute phase and maintenance therapy phase with severe positive symptoms (e.g. delusions, hallucinations, thinking disorders, hostility and suspicion) and/or negative symptoms (e.g. apathy, emotional and social withdrawal, lack of speech). Olanzapine can also alleviate the secondary emotional symptoms caused by schizophrenia and related diseases. Olanzapine can effectively maintain the relief of clinical symptoms in patients who have achieved initial efficacy and need continue treatment.
【Dosage and Administration】
The recommended starting dose for olanzapine is 10 mg (2 tablets) per day without regard to meals, because the absorption is not affected by meals. The daily dose range of olanzapine is 5 mg (1 tablet) to 20 mg (4 tablets). The daily dose should be adjusted according to the clinical condition. An increase to a dose greater than 10 mg/day (2 tablets) is recommended only after clinical assessment. If permitted by clinical conditions, the starting dose of elderly patients is 5 mg (1 tablet) per day. In patients with severe renal impairment or moderate hepatic dysfunction, the starting dose is also 5 mg (1 tablet) per day. If there are a number of factors that can slow the metabolism of olanzapine (female, elderly, non-smokers), the lower starting dose is recommended. Olanzapine has not yet been studied in people under age 18.
2001: First-to-market generic drug in China
2004: Included in China’s National Reimbursement Drug List (NRDL)
2010: National Key New Product
2013: Included in the National Torch Program
2014: Second Prize for the Advancement of Science and Technology
2018: First (olanzapine) to pass consistency evaluation in China